Compare Eli Lilly And Co (LLY) vs Starbucks Corp (SBUX) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Starbucks (SBUX) trades at $104.64, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The stock shows mixed earnings performance, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, while revenue growth remains steady. Recent news highlights cost-cutting initiatives, including a $400 million AI-driven software reduction plan, and strong channel development growth of 39% year-over-year in Q2 2026.

The investment outlook is cautiously optimistic, with a consensus price target of $108.86 offering modest upside. Key opportunities include margin expansion from cost efficiencies and dividend growth, but risks involve high valuation multiples, competitive pressures, and inconsistent earnings performance. Analyst sentiment is balanced with 47% buy and hold ratings each.